Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891969019> ?p ?o ?g. }
- W2891969019 abstract "Abstract The lack of highly sensitive and specific diagnostic biomarkers is a major contributor to the poor outcomes of patients with hepatocellular carcinoma (HCC), the second-most common cause of cancer deaths worldwide. We sought to develop a clinically convenient and minimally-invasive approach that can be deployed at scale for the sensitive, specific, and highly reliable diagnosis of HCC, and to evaluate the potential prognostic value of this approach. The study cohort comprised of 2,728 subjects, including HCC patients (n = 1,208), controls (n = 965) (572 healthy individuals and 393 patients with benign lesions), as well as patients with chronic hepatitis B infection (CHB) (n =291), liver cirrhosis (LC) (n = 110), and cholangiocarcinoma (CCC) (n = 154), was recruited from three major liver cancer hospitals in Shanghai, China, from July 2016 to November 2017. Circulating cell-free DNA (cfDNA) were collected from plasma samples from these individuals before surgery or any radical treatment. Applying our 5hmC-Seal technique, the summarized 5-hydroxymethylcytosine (5hmC) profiles in cfDNA were obtained. Molecular annotation analysis suggested that the profiled 5hmC loci in cfDNA were enriched with liver tissue-derived regulatory markers (e.g., H3K4me1). We showed that a weighted diagnostic score (wd-score) based on 117 genes detected using the summarized 5hmC profiles in cfDNA accurately distinguished HCC patients from controls (AUC = 95.1%; 95% CI, 93.6-96.5%) in the validation set, markedly outperformed α-fetoprotein (AFP) with superior sensitivity. The wd-scores, which not only detected early BCLC stages (e.g., Stage 0: AUC = 96.2%; 95% CI,94.1-98.4%) and small tumors (e.g., < 2 cm: AUC = 95.7%; 95% CI: 93.6-97.7%), also showed high capacity for distinguishing HCC from non-cancer patients with CHB/LC (AUC = 80.2%; 95% CI, 75.8-84.6%). Moreover, the prognostic value of 5hmC markers in cfDNA was evaluated for HCC recurrence, showing that a weighted prognostic score (wp-score) based on 16 marker genes predicted the recurrence risk (HR = 6.67; 95% CI, 2.81-15.82, p < 0.0001) in 555 patients who have been followed up after surgery. In conclusion, we have developed and validated a robust 5hmC-based diagnostic model that can be applied routinely with clinically feasible amount of cfDNA (e.g., from ~2-5 mL of plasma). Applying this new approach in the clinic could significantly improve the clinical outcomes of HCC patients, for example by early detection of those patients with surgically resectable tumors or as a convenient disease surveillance tool for recurrence." @default.
- W2891969019 created "2018-09-27" @default.
- W2891969019 creator A5003599636 @default.
- W2891969019 creator A5009289697 @default.
- W2891969019 creator A5010738468 @default.
- W2891969019 creator A5011147985 @default.
- W2891969019 creator A5011835067 @default.
- W2891969019 creator A5017352295 @default.
- W2891969019 creator A5019165930 @default.
- W2891969019 creator A5020733153 @default.
- W2891969019 creator A5021277858 @default.
- W2891969019 creator A5025087223 @default.
- W2891969019 creator A5025174527 @default.
- W2891969019 creator A5026283201 @default.
- W2891969019 creator A5029634246 @default.
- W2891969019 creator A5030485564 @default.
- W2891969019 creator A5031371726 @default.
- W2891969019 creator A5036106073 @default.
- W2891969019 creator A5037879414 @default.
- W2891969019 creator A5038541421 @default.
- W2891969019 creator A5042624998 @default.
- W2891969019 creator A5046173951 @default.
- W2891969019 creator A5049407947 @default.
- W2891969019 creator A5053582934 @default.
- W2891969019 creator A5053820568 @default.
- W2891969019 creator A5061494199 @default.
- W2891969019 creator A5065181780 @default.
- W2891969019 creator A5076640232 @default.
- W2891969019 creator A5077954433 @default.
- W2891969019 creator A5080930329 @default.
- W2891969019 creator A5081961473 @default.
- W2891969019 creator A5085243153 @default.
- W2891969019 creator A5086674805 @default.
- W2891969019 creator A5087110966 @default.
- W2891969019 creator A5091114864 @default.
- W2891969019 date "2018-09-23" @default.
- W2891969019 modified "2023-10-18" @default.
- W2891969019 title "5-Hydroxymethylcytosines from Circulating Cell-free DNA as Diagnostic and Prognostic Markers for Hepatocellular Carcinoma" @default.
- W2891969019 cites W1757407923 @default.
- W2891969019 cites W1913581775 @default.
- W2891969019 cites W1963853602 @default.
- W2891969019 cites W1972602773 @default.
- W2891969019 cites W1976768672 @default.
- W2891969019 cites W1987370132 @default.
- W2891969019 cites W1989457196 @default.
- W2891969019 cites W2000307707 @default.
- W2891969019 cites W2014739095 @default.
- W2891969019 cites W2029632944 @default.
- W2891969019 cites W2042839116 @default.
- W2891969019 cites W2048436671 @default.
- W2891969019 cites W2050434028 @default.
- W2891969019 cites W2068379194 @default.
- W2891969019 cites W2070778756 @default.
- W2891969019 cites W2076154138 @default.
- W2891969019 cites W2089470652 @default.
- W2891969019 cites W2094873643 @default.
- W2891969019 cites W2103081012 @default.
- W2891969019 cites W2109643319 @default.
- W2891969019 cites W2122825543 @default.
- W2891969019 cites W2162519578 @default.
- W2891969019 cites W2164252555 @default.
- W2891969019 cites W2171104739 @default.
- W2891969019 cites W2234453634 @default.
- W2891969019 cites W2272984102 @default.
- W2891969019 cites W2324787799 @default.
- W2891969019 cites W2590954301 @default.
- W2891969019 cites W2749613778 @default.
- W2891969019 cites W2755906204 @default.
- W2891969019 cites W2790122515 @default.
- W2891969019 doi "https://doi.org/10.1101/424978" @default.
- W2891969019 hasPublicationYear "2018" @default.
- W2891969019 type Work @default.
- W2891969019 sameAs 2891969019 @default.
- W2891969019 citedByCount "1" @default.
- W2891969019 countsByYear W28919690192019 @default.
- W2891969019 crossrefType "posted-content" @default.
- W2891969019 hasAuthorship W2891969019A5003599636 @default.
- W2891969019 hasAuthorship W2891969019A5009289697 @default.
- W2891969019 hasAuthorship W2891969019A5010738468 @default.
- W2891969019 hasAuthorship W2891969019A5011147985 @default.
- W2891969019 hasAuthorship W2891969019A5011835067 @default.
- W2891969019 hasAuthorship W2891969019A5017352295 @default.
- W2891969019 hasAuthorship W2891969019A5019165930 @default.
- W2891969019 hasAuthorship W2891969019A5020733153 @default.
- W2891969019 hasAuthorship W2891969019A5021277858 @default.
- W2891969019 hasAuthorship W2891969019A5025087223 @default.
- W2891969019 hasAuthorship W2891969019A5025174527 @default.
- W2891969019 hasAuthorship W2891969019A5026283201 @default.
- W2891969019 hasAuthorship W2891969019A5029634246 @default.
- W2891969019 hasAuthorship W2891969019A5030485564 @default.
- W2891969019 hasAuthorship W2891969019A5031371726 @default.
- W2891969019 hasAuthorship W2891969019A5036106073 @default.
- W2891969019 hasAuthorship W2891969019A5037879414 @default.
- W2891969019 hasAuthorship W2891969019A5038541421 @default.
- W2891969019 hasAuthorship W2891969019A5042624998 @default.
- W2891969019 hasAuthorship W2891969019A5046173951 @default.
- W2891969019 hasAuthorship W2891969019A5049407947 @default.
- W2891969019 hasAuthorship W2891969019A5053582934 @default.
- W2891969019 hasAuthorship W2891969019A5053820568 @default.
- W2891969019 hasAuthorship W2891969019A5061494199 @default.